ALNYLAM PHARMACEUTICALS, INC.
ALNYUnited States
74 filed reports · 506 financial concepts · 12 earnings calls · 1 media appearance
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Filed reports
74 reports · Jun 2014 to Sep 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 119 guidance figures, 37 earnings-release figures, 43 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 38 | 4,841 | Jun 2014 to Sep 2026 |
| Current · 8-KSEC EDGAR | 24 | 139 | Mar 2020 to Sep 2026 |
| Annual · 10-KSEC EDGAR | 12 | 4,974 | Dec 2014 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q3 | 10-Q | 2026-09-30 | 2026-10-29 | 384 | Open |
| FY2026 Q3 | 8-K | 2026-09-30 | 2026-10-29 | 45 | Open |
| FY2026 Q2 | 10-Q | 2026-06-30 | 2026-07-30 | 242 | Open |
| FY2026 Q2 | 8-K | 2026-06-30 | 2026-07-30 | 8 | Open |
| FY2026 Q1 | 8-K | 2026-03-31 | 2026-04-30 | 7 | Open |
| FY2026 Q1 | 10-Q | 2026-03-31 | 2026-04-30 | 228 | Open |
| FY2025 | 10-K | 2025-12-31 | 2026-02-12 | 910 | Open |
| FY2025 Q4 | 8-K | 2025-12-31 | 2026-01-12 | 5 | Open |
| FY2025 Q3 | 10-Q | 2025-09-30 | 2025-10-30 | 181 | Open |
| FY2025 Q3 | 8-K | 2025-09-30 | 2025-10-30 | 4 | Open |
| FY2025 Q2 | 10-Q | 2025-06-30 | 2025-07-31 | 142 | Open |
| FY2025 Q2 | 8-K | 2025-06-30 | 2025-07-31 | 4 | Open |
Financial data
506 concepts · 9,954 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial475 concepts · 9,053 facts · Feb 2012 to Sep 2026
- Cash and cash equivalents at carrying value69 · Dec 2012 to Sep 2026
- Comprehensive income net of tax69 · Dec 2012 to Sep 2026
- Net income loss69 · Dec 2012 to Sep 2026
- Nonoperating income expense69 · Dec 2012 to Sep 2026
- Operating income loss69 · Dec 2012 to Sep 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax69 · Dec 2012 to Sep 2026
- Other nonoperating income expense69 · Dec 2012 to Sep 2026
- Research and development expense69 · Dec 2012 to Sep 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest67 · Dec 2012 to Sep 2026
- Increase decrease in prepaid deferred expense and other assets67 · Dec 2012 to Sep 2026
- Payments to acquire available for sale securities debt67 · Dec 2012 to Sep 2026
- Payments to acquire property plant and equipment67 · Dec 2012 to Sep 2026
- Proceeds from issuance of shares under incentive and share based compensation plans including stock options67 · Dec 2012 to Sep 2026
- Share based compensation67 · Dec 2012 to Sep 2026
- Stockholders equity (US GAAP)66 · Dec 2012 to Sep 2026
- Retained earnings accumulated deficit65 · Dec 2013 to Sep 2026
- Accounts payable current64 · Dec 2013 to Sep 2026
- Accrued liabilities current64 · Dec 2013 to Sep 2026
- Accumulated other comprehensive income loss net of tax64 · Dec 2013 to Sep 2026
- Additional paid in capital common stock64 · Dec 2013 to Sep 2026
- Assets64 · Dec 2013 to Sep 2026
- Assets current64 · Dec 2013 to Sep 2026
- Available for sale securities debt securities current64 · Dec 2013 to Sep 2026
- Common stock par or stated value per share64 · Dec 2013 to Sep 2026
Product3 concepts · 734 facts · Dec 2017 to Sep 2026
- Revenue693 · Dec 2017 to Sep 2026
- Accounts Receivable, Net39 · Dec 2018 to Jun 2026
- Chargebacks and Rebates2 · Dec 2018
Guidance15 concepts · 119 facts · May 2020 to Oct 2026
- Revenue Guidance32 · May 2020 to Jul 2026
- Revenue Growth Guidance20 · Jan 2021 to Oct 2026
- Revenue Guidance (Net revenues from collaborations and royalties)12 · Feb 2021 to Oct 2026
- Revenue Growth Guidance (Net Product Revenue; Constant currency)10 · May 2023 to Oct 2026
- Revenue Guidance (Combined net product revenues for ONPATTRO, GIVLAARI, and OXLUMO)10 · Feb 2021 to May 2023
- Operating Margin Guidance8 · Jan 2026 to Jul 2026
- Revenue Growth Guidance (Net Product Revenue)6 · May 2023 to Feb 2024
- Revenue Growth Guidance (net product revenues; At current exchange rates)4 · Jul 2026 to Oct 2026
- Revenue Guidance (collaborations and royalties)4 · Aug 2023 to Feb 2024
- Revenue Guidance (net product revenues; At current exchange rates)4 · Jul 2026 to Oct 2026
- Operating Margin Guidance (Adjusted (non-GAAP))2 · Oct 2026
- Revenue Guidance (collaborations and royalties; At current exchange rates)2 · Jul 2026
- Revenue Guidance (Net product revenues)2 · Feb 2024
- Revenue Guidance (ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO)2 · Aug 2023
- Revenue Growth Guidance (combined net product revenues for our three wholly owned commercial brands)1 · Feb 2021
KPI11 concepts · 36 facts · Sep 2025 to Sep 2026
- Income before income taxes4 · Sep 2025 to Sep 2026
- Income from operations4 · Sep 2025 to Sep 2026
- Net income4 · Sep 2025 to Sep 2026
- Total net product revenues4 · Sep 2025 to Sep 2026
- Total operating costs and expenses4 · Sep 2025 to Sep 2026
- Total other expense, net4 · Sep 2025 to Sep 2026
- Total revenues4 · Sep 2025 to Sep 2026
- Common stock, $0.01 par value per share, 250,000 shares authorized; 133,875 shares issued and outstanding as of September 30, 2026; 132,376 shares issued and outstanding as of December 31, 20252 · Dec 2025 to Sep 2026
- Other2 · Sep 2025 to Sep 2026
- Regeneron Pharmaceuticals2 · Sep 2025 to Sep 2026
- Roche2 · Sep 2025 to Sep 2026
Segment2 concepts · 12 facts · Mar 2025 to Sep 2026
- Research and development expense6 · Mar 2025 to Sep 2026
- Selling general and administrative expense6 · Mar 2025 to Sep 2026
Segments
746 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service10 members · 734 facts
- ONPATTRO152 · Dec 2018 to Sep 2026
- GIVLAARI148 · Dec 2018 to Sep 2026
- OXLUMO133 · Dec 2018 to Sep 2026
- Amvuttra106 · Dec 2020 to Sep 2026
- Product70 · Dec 2017 to Sep 2026
- Product39 · Dec 2018 to Jun 2026
- Royalty34 · Dec 2019 to Sep 2026
- Collaborations24 · Dec 2021 to Sep 2026
- Rare14 · Dec 2023 to Sep 2026
- TTR14 · Dec 2023 to Sep 2026
Statement business segments1 member · 12 facts
- Single Reportable12 · Mar 2025 to Sep 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary112 claims from 8 reports · Dec 2024 to Sep 2026
- Management discussion (MD&A) commentary175 claims from 9 reports · Sep 2024 to Sep 2026
- Risk-factor changes222 claims from 11 reports · Dec 2015 to Dec 2025
- Risk factors556 risks from 12 annual reports · 2014 to 2025
Earnings calls
12 calls · Feb 2024 to Oct 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q32026-10-29
- FY2026 Q22026-07-30
- FY2026 Q12026-04-30
- FY2025 Q42026-02-12
- FY2025 Q32025-10-30
- FY2025 Q22025-07-31
- FY2025 Q12025-05-01
- FY2024 Q42025-02-13
- FY2024 Q32024-10-31
- FY2024 Q22024-08-01
- FY2024 Q12024-05-02
- FY2023 Q42024-02-15
Executive media
1 appearancePodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances1 · Apr 2022
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of ALNYLAM PHARMACEUTICALS, INC. (ALNY) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.